Best Infectious Diseases Companies in France

Developer of drugs for neuromuscular and age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Other drug candidate, Macuneos (BIO201) for the treatment of retinal diseases, including dry AMD and Stargardt disease.

Developer of vaccines against constantly mutating pathogens. The company leverages oligoDOM a novel proprietary nanoparticles technology specifically designed to trigger superior T-cell responses. The company's lead candidate is OVX836 against influenza and coronavirus.

Developer of therapeutics for chronic inflammatory diseases. The lead drug candidate obefazimod is an oral, first-and-only small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response. It is also develops products for Ulcerative Colitis, crohn's disease, and more.

Vaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company strategy is to develop vaccines till the proof-of-concept and license to pharma companies for further development. The company also offers contract research services for vaccine research & development including fabrication & characterization of nanoparticles, formulations with active components, optimisation of formulations.

Antabio is a French early-stage drug discovery company developing compounds for multi-drug resistant bacterial infections. The 2 lead programs are Metallo Beta-Lactamases inhibitors against E. coli NDM-1 strains and Pseudomonas Biofilms inhibitors in chronic respiratory infections. In 2013 and 2015 received funding from Wellcome Trust for EUR 4.7M and EUR 4 M respectively. The first candidate is a novel, safe and efficacious inhibitor of bacterial MBLs. It will be co-administered with a carbapenem to treat hospitalized patients suffering from complicated Gram-negative infections. The second candidate is an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting both the virulence and persistence of biofilm-adapted infections.

Developer of prophylactic vaccines for infectious diseases. The company's lead candidate is VLA1553 is a live-attenuated, single dose vaccine targeting the chikungunya virus. Other products includes VLA15 for Lyme Disease, VLA84 for Clostridium difficile, and VLA1601 for zika virus

Funding rounds

• Oct 2022Post IPO$102M
• Jun 2022Post IPO$94.9M
• Feb 2022Grant (prize money)—
• Nov 2021Post IPO—

Founders & team

Thomas LingelbachPresident & CEO

Investors

European Investment Bank, Bpifrance, Deep Track Capital, CEPI, Scottish Investment Bank, Pfizer

Tech stack

Apache Http ServerCdnjsCloudflareCloudflare Bot ManagementContact Form 7Cookieyes

Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection. By using the lentiviral immunotherapy platform the company has developed therapeutic vaccines for HIV, Hepatitis-B, Tuberculosis, and Adult T-cell Lymphoma-Leukaemia (ATL) induced by Human T-Lymphotropic Virus Type I (HTLV-1) infection.

Funding rounds

• Feb 2021Series D$20M
• Apr 2017Series C$5.8M
• Jan 2015Grant (prize money)$2.1M
• Oct 2013Series C$19.9M

Founders & team

Ye TianCEO

Investors

FGP Capital, iXLife Capital, Bpifrance

Tech stack

WordpressMysqlPhpWindows ServerWordpress Super CacheDivi

Developer of drugs against antibiotic-resistant bacteria. The lead drug candidate NAIAP Ol20-01 is able to eliminate persistent bacteria. Another candidate MIAMI-OL20-11 a new molecule discovered in algae has the property of boosting the immune system which helps in preventing nosocomial diseases. The company has also developed a proprietary screening platform to test and modify molecules.

Developer of protein-based vaccine platform designed for multiple pathogens. The company's vaccines are built around a humanized monoclonal antibody, which is merged with regions of pathogens of interest, targeting the CD40 molecule expressed by dendritic cells, enabling healthcare providers to have access to vaccines for treating diseases such as HIV, SARS-CoV-2 variants, and human papillomavirus-related cancers.

Founders & team

Remi Gaston-DreyfusCo-FounderYves LevyCo-Founder

Investors

In-Q-Tel, Geoffrey Duyk, Andre Jacques Auberton Herve, Jean-Paul Kress, Alain Tingaud, Giorgio Anania

Pherecydes Pharma is a French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections. The main bacteria they are targeting include E.coli and P. aeruginosa which are common, and fatal, infections in burn victims. Their phage therapy clinical trial, phase I/II for burn victims, called PHAGOBURN was funded by the European Govt. (EUR 3.85 M). in Jun.2015, they launched the project PNEUMOPHAGE, targeted at developing phage therapies for acute respiratory infections/ ventilator-acquired pneumonia caused by P. aeruginosa. Since Jan.2015, they are part of the PHOSA project aimed at developing phage treatments for Diabetic Foot Ulcers and Bone Joint infections, caused by staphylococci species.

Developer of molecular diagnostic tests for infectious diseases. It offers PCR-based diagnostic assays that detect attomolar concentrations of pathogens in samples like saliva, nose swabs or interstitial fluid. It offers diagnostics kit for detection of the bacterial carrier of Lyme disease, SARS-CoV-2, Zika and Chikungunya Virus.

Funding rounds

• May 2024Seed$1.6M

Founders & team

Margot KarlikowCo-FounderGuillaume HorreardCo-Founder

Investors

CentraleSupelec

Fab’entech develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications. Its lead candidate FBF-001 (Phase1/2) consists o fragments of specific equine polyclonal immunoglobulins directed against H5N1 avian influenza virus. Other polyclonal antibodies in development are directed against Avian influenza viruses type H7, Ebola, Crimean-Congo Hemorrhagic Fever (CCHF), MERS and others.